title: Metastasis of lobular breast carcinoma to the uterus in a patient under anastrozole therapy.
abstract: BACKGROUND
  Metastasis of extragenital neoplasms to the uterus are rarely encountered, and usually occur as a manifestation of advanced disease. Lobular carcinoma is the most common type of breast cancer that metastasizes to the uterus.
  
  
  METHODS
  We report on a 56-year-old woman who 3 years previously was diagnosed with invasive lobular carcinoma of the breast and was treated with surgery followed by chemotherapy and radiotherapy. While the patient was on adjuvant anastrozole therapy for 2 years, she complained of vaginal bleeding. Because of endometrial thickening and a uterine leiomyoma detected during abdominal ultrasonographic ex-amination, a total hysterectomy with bilateral salpingo-oophorectomy was performed. Histopathologic examination of the specimens revealed carcinoma infiltration of the myometrium, endometrium, cervix, uterine tube, and left ovary. Immunohistochemical staining of tumoral cells with pancytokeratin and gross cystic disease fluid protein (GCDFP-15) proved the diagnosis of metastatic lobular breast carcinoma to the uterus.
  
  
  CONCLUSIONS
  To our knowledge, this is the second case of lobular breast carcinoma metastasized to the uterus under anastrozole therapy. In women with lobular breast cancer under adjuvant anastrozole therapy, who present with vaginal bleeding, uterine metastasis of lobular carcinoma should be considered in the differential diagnosis.
authors: Department of Medical Oncology, Dr Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey.
authors: Basak B O
authors: BB
authors: Ustaalioglu
authors: Ahmet
authors: A
authors: Bilici
authors: Mesut
authors: M
authors: Seker
authors: Tarik
authors: T
authors: Salman
authors: Mahmut
authors: M
authors: Gumus
authors: Nagehan O
authors: NO
authors: Barisik
authors: Taflan
authors: T
authors: Salepci
authors: Mustafa
authors: M
authors: Yaylaci
mesh_terms: D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000150:complications* / Q000188:drug therapy*; D018275:Carcinoma, Lobular / Q000139:chemically induced* / Q000175:diagnosis / Q000556:secondary*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D008875:Middle Aged; D009570:Nitriles / Q000009:adverse effects* / Q000627:therapeutic use*; D014230:Triazoles / Q000009:adverse effects* / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000139:chemically induced* / Q000175:diagnosis / Q000556:secondary*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D014230:Triazoles; D000077384:Anastrozole